Andrzej Siwiec

Andrzej focuses on pharmaceutical and medical law as well as industrial property law and commercial law issues specific to the Life Sciences sector. He has been advising pharmaceutical companies and health care providers for a number of years.

Andrzej advises clients on projects concerning marketing medicinal products, reimbursement processes, and contracts typical for the pharmaceutical market. He provides holistic support for complex interdisciplinary projects involving regulatory, reimbursement, industrial property, and competition law. These projects include European market access strategies for new medicinal products (including orphan drugs), products’ rights acquisition transactions covering several European countries, and strategies for entering the generic drug market from day 1 after the original product IP protection expires.

He also assists health care providers in their day-to-day operations and develops his expertise in the field of intellectual property disputes, both patent and trademark.

He is a highly valued speaker at life sciences events and participates in the work on legislative changes in pharmaceutical and reimbursement law.

Andrzej has been with DBS since 2016. He has served as a Partner since 2023.

Prior to joining DBS, Andrzej worked as an in-house counsel at one of the largest clinical hospitals in Poland. With 32 departments, 42,000 hospital admissions every year and 4,200 staff, the hospital serves as the main medical centre for the population of some 6 million people in South East Poland.

He serves as external head of legal for an international pharmaceutical company specialising in orphan drugs.

Cracow Bar Association

Chambers Global Practice Guide (Poland) - Healthcare: Medical Devices 2025 (co-author)

Parallel import of medicinal products: regulatory update (European Pharmaceutical Review Issue 1 2023 - co-author)

A New Pharmaceutical Strategy for Europe – anticipated directions for EU legislation in the field of medicinal products (Świat Przemysłu Farmaceutycznego 1/2021 – co-author)

Pharmaceutical manufacturing in Poland from the perspective of the proposed amendment to the Reimbursement Act (Świat Przemysłu Farmaceutycznego 4/2021 – co-author)

New EU regulations for veterinary medicinal products (Świat Przemysłu Farmaceutycznego 1/2022 – co-author)

New regulations on post-marketing quality control (Świat Przemysłu Farmaceutycznego 4/2022 – co-author)

A revolution in reimbursement of medicines – key changes from the perspective of pharmaceutical companies (Świat Przemysłu Farmaceutycznego 3/2023 – co-author)

How will the European Health Data Space affect the pharmaceutical industry? (Świat Przemysłu Farmaceutycznego 3/2024 – co-author)

Avanzanite Bioscience

Teva Pharmaceuticals Polska

Chambers Europe – Ranked in Life Sciences (2026)

The Legal 500 EMEA – Recommended Lawyers, Healthcare and Life Sciences (2024-2025)